tiprankstipranks
Trending News
More News >
InnoCare Pharma Ltd. (HK:9969)
:9969
Hong Kong Market
Advertisement

InnoCare Pharma Ltd. (9969) Drug Pipeline

Compare
2 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Rituximab, Orelabrutinib, Bendamustine Injection
Mantle Cell Lymphoma
Phase III
Recruiting
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Apr 09, 2024
Icp-248, Obinutuzumab (G), Rituximab (R)
Mature B-Cell Malignancies
Phase I
Recruiting
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
Apr 02, 2024

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does InnoCare Pharma Ltd. (9969) have in its pipeline
      9969 is currently developing the following drugs: Rituximab, Orelabrutinib, Bendamustine Injection, Icp-248, Obinutuzumab (G), Rituximab (R). These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis